TY  - GEN
AU  - Folegatti,Pedro M
AU  - Bittaye,Mustapha
AU  - Flaxman,Amy
AU  - Lopez,Fernando Ramos
AU  - Bellamy,Duncan
AU  - Kupke,Alexandra
AU  - Mair,Catherine
AU  - Makinson,Rebecca
AU  - Sheridan,Jonathan
AU  - Rohde,Cornelius
AU  - Halwe,Sandro
AU  - Jeong,Yuji
AU  - Park,Young-Shin
AU  - Kim,Jae-Ouk
AU  - Song,Manki
AU  - Boyd,Amy
AU  - Tran,Nguyen
AU  - Silman,Daniel
AU  - Poulton,Ian
AU  - Datoo,Mehreen
AU  - Marshall,Julia
AU  - Themistocleous,Yrene
AU  - Lawrie,Alison
AU  - Roberts,Rachel
AU  - Berrie,Eleanor
AU  - Becker,Stephan
AU  - Lambe,Teresa
AU  - Hill,Adrian
AU  - Ewer,Katie
AU  - Gilbert,Sarah
TI  - Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
SN  - 1474-4457
PY  - 2020///0909
KW  - Adult
KW  - Antibodies, Neutralizing
KW  - immunology
KW  - Antibodies, Viral
KW  - Coronavirus Infections
KW  - prevention & control
KW  - Dose-Response Relationship, Immunologic
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Female
KW  - Humans
KW  - Immunogenicity, Vaccine
KW  - Male
KW  - Middle Aged
KW  - Middle East Respiratory Syndrome Coronavirus
KW  - genetics
KW  - United Kingdom
KW  - Vaccines, DNA
KW  - Viral Vaccines
KW  - administration & dosage
KW  - Young Adult
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1473-3099(20)30160-2
ER  -